TY - JOUR
T1 - In-hospital infective endocarditis following transcatheter aortic valve replacement
T2 - a cross-sectional study of the National Inpatient Sample database in the USA
AU - Yeo, I.
AU - Kim, L. K.
AU - Park, S. O.
AU - Wong, S. C.
N1 - Publisher Copyright:
© 2018 The Healthcare Infection Society
PY - 2018/12
Y1 - 2018/12
N2 - Background: While the utilization of transcatheter aortic valve replacement (TAVR) for patients with severe aortic stenosis has been increasing, in-hospital infective endocarditis (IE) following TAVR has not been well described. Aim: To identify in-hospital IE following TAVR. Methods: All patients who underwent TAVR between 2012 and 2014 were identified using the National Inpatient Sample database. Multi-variate logistic regression was performed to identify the predictors of in-hospital IE after TAVR. Findings: Of the 41,025 patients who received TAVR, 120 patients (0.3%) developed in-hospital IE. Viridans group streptococci (20.8%) was the most frequent causative organism for in-hospital IE, followed by Staphylococcus aureus (16.7%) and enterococci (8.3%). Patients who developed in-hospital IE after TAVR had significantly higher rates of death (20.8% vs 4.1%, P<0.001), septic shock (16.7% vs 0.8%, P<0.001), cardiogenic shock (12.5% vs 3.4%, P=0.02), acute kidney injury requiring haemodialysis (16.7% vs 1.6%, P<0.001), bleeding requiring transfusion (29.2% vs 11.3%, P=0.01), myocardial infarction (12.5% vs 2.1%, P<0.001) and permanent pacemaker removal (4.2% vs 0.05%, P<0.001) compared with patients without IE. Independent predictors of in-hospital IE after TAVR include younger age [odds ratio (OR) 0.92, 95% confidence interval (CI) 0.89–0.95], drug abuse (OR 48.9, 95% CI 6.9–347.3) and human immunodeficiency virus (HIV) infection (OR 7.8, 95% CI 1.4–44.4). Conclusion: IE occurred in 0.3% of patients after TAVR during the same hospitalization, resulting in higher rates of adverse outcomes including mortality. Patients with younger age, a history of drug abuse or HIV infection are at greater risk of in-hospital IE following TAVR, and would benefit from vigilant preventive measures perioperatively.
AB - Background: While the utilization of transcatheter aortic valve replacement (TAVR) for patients with severe aortic stenosis has been increasing, in-hospital infective endocarditis (IE) following TAVR has not been well described. Aim: To identify in-hospital IE following TAVR. Methods: All patients who underwent TAVR between 2012 and 2014 were identified using the National Inpatient Sample database. Multi-variate logistic regression was performed to identify the predictors of in-hospital IE after TAVR. Findings: Of the 41,025 patients who received TAVR, 120 patients (0.3%) developed in-hospital IE. Viridans group streptococci (20.8%) was the most frequent causative organism for in-hospital IE, followed by Staphylococcus aureus (16.7%) and enterococci (8.3%). Patients who developed in-hospital IE after TAVR had significantly higher rates of death (20.8% vs 4.1%, P<0.001), septic shock (16.7% vs 0.8%, P<0.001), cardiogenic shock (12.5% vs 3.4%, P=0.02), acute kidney injury requiring haemodialysis (16.7% vs 1.6%, P<0.001), bleeding requiring transfusion (29.2% vs 11.3%, P=0.01), myocardial infarction (12.5% vs 2.1%, P<0.001) and permanent pacemaker removal (4.2% vs 0.05%, P<0.001) compared with patients without IE. Independent predictors of in-hospital IE after TAVR include younger age [odds ratio (OR) 0.92, 95% confidence interval (CI) 0.89–0.95], drug abuse (OR 48.9, 95% CI 6.9–347.3) and human immunodeficiency virus (HIV) infection (OR 7.8, 95% CI 1.4–44.4). Conclusion: IE occurred in 0.3% of patients after TAVR during the same hospitalization, resulting in higher rates of adverse outcomes including mortality. Patients with younger age, a history of drug abuse or HIV infection are at greater risk of in-hospital IE following TAVR, and would benefit from vigilant preventive measures perioperatively.
KW - Aortic stenosis
KW - In-hospital infective endocarditis
KW - Transcatheter aortic valve replacement
UR - http://www.scopus.com/inward/record.url?scp=85050089644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050089644&partnerID=8YFLogxK
U2 - 10.1016/j.jhin.2018.05.014
DO - 10.1016/j.jhin.2018.05.014
M3 - Article
C2 - 29803809
AN - SCOPUS:85050089644
SN - 0195-6701
VL - 100
SP - 444
EP - 450
JO - Journal of Hospital Infection
JF - Journal of Hospital Infection
IS - 4
ER -